TransCode Therapeutics (RNAZ) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on TransCode Therapeutics (RNAZ) is Moderate Underperform.

The composite score behind that read is -0.48, weighing +0.44 of bullish evidence against -0.53 bearish.

TransCode Therapeutics last closed at $1.76, +12.10% on the session.

Against the IVW growth benchmark the position is +11.18% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

16 graded predictions for RNAZ so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks TransCode Therapeutics in the 99th percentile on return on equity, where 100 is best.

TransCode Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $26.58M.

StockMap tracks TransCode Therapeutics as the 299th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite TransCode Therapeutics ranks 329th of 344 in the group, against a group median of -0.21.